Oncology
 |
|
12 june 2020 18:31:54 |
| Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II trial by the West Japan Oncology Group (BMC Cancer) |
|
Tweet Ramucirumab (RAM) with weekly paclitaxel (wPTX) is a standard second-line therapy for advanced or recurrent gastric cancer. Nanoparticle albumin-bound paclitaxel (nab-PTX), an albumin-bound form of PTX, was de... |
| 304 viewsCategory: Oncology |
 Viral infection and glioma: a meta-analysis of prognosis (BMC Cancer)Correlation study between flash dual source CT perfusion imaging and regional lymph node metastasis of non-small cell lung cancer (BMC Cancer) 
|
| blog comments powered by Disqus |
MyJournals.org
The latest issues of all your favorite science journals on one page
The latest issues of all your favorite science journals on one page
